Basically we are exploring novel synthetic lethal interactors of BRCA2 gene. Later targeting synthetic lethal interactors using small molecules inhibitors (drugs/chemicals) and siRNA for selective killing of BRCA2-deficient cancer cells. We are also developing nanomaterials for the better delivery of siRNA to achieve therapeutic effects.